Untitled

Ferro-Flores, Guillermina; Ramı́rez, Flor de Marı́a; Martínez-mendoza, M.G.; Murphy, Consuelo Arteaga de; Pedraza-López, Martha; García-Salinas, L.

doi:10.1023/a:1015077707567

Cited by 4 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bifunctional chelators designed to accommodate the structural preferences of the [ReO] 3+ offer a more reliable strategy. Use and further design [20] of tetradentate ligands containing a combination of amino/amido and thiolate donors [21] such as MAG3 [22] (Figure 3a) and cysteine-containing amino acid sequences [23,24] (Figure 2), developed in the 1990s, [11] have remained popular for attachment to lipids [25,26] and peptides, [22,[27][28][29][30][31][32] or simple complexes designed for rapid renal excretion in the context of radionuclide therapy during balloon angioplasty, [33,34] has continued. Re analogues were synthesised and shown to have identical structure and isomerism [6,7] (Figure 3b) and biodistribution (targeting medullary thyroid carcinoma and bone metastases in prostate, lung and breast cancer) [4,5].…”

Section: Rhenium (V) Complexesmentioning

confidence: 99%

Rhenium-188 Radiochemistry: Challenges and Prospects

Blower¹

2017

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

After a lull in development of new chemistry for rhenium-188 and technetium-99m since 2000, there has been new investment in production facilities for Mo-99/Tc-99m coupled with increasing interest in rhenium-188 radionuclide therapy, particularly in developing countries. Much of the chemistry developed in the 1990s is not readily amenable to supporting modern radiopharmaceutical development, which places increased emphasis on molecular targeted radiopharmaceuticals. Consequently there is a need for new radiolabelling chemistry to incorporate these radionuclides into biomolecules using simple, kit-based methodology. This review provides an update on progress towards simple rhenium-188 labelling methods since 2000.

show abstract

Section: Rhenium (V) Complexesmentioning

confidence: 99%

Rhenium-188 Radiochemistry: Challenges and Prospects

Blower¹

2017

Int. J. Nucl. Medi. Res.

View full text Add to dashboard Cite

show abstract

“…335 The radioisotope has also been conjugated to other targeting molecules using bifunctional chelators. 106,336 There is growing interest in development of radiopharmaceuticals containing lutetium-177 as a therapeutic radionuclide. It has been incorporated into polyaminophosphonates for bone cancer treatment, 337 and into peptides using DOTA 338 and other bifunctional chelators.…”

Section: Lanthanidesmentioning

confidence: 99%